Molecular structure and biochemical properties of the HCCH-Zn2+ site in HIV-1 Vif

Biochemistry

Volumn 48, Issue 33, 2009, Pages 7969-7978

  Giri, Kalyan ^a   Scott, Robert A ^b   Maynard, Ernest L ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGREGATION PROPERTY; APOLIPOPROTEIN B; BIOCHEMICAL PROPERTIES; BIOMIMETIC PEPTIDES; C-TERMINUS; CD SPECTROSCOPY; COORDINATION NUMBER; CYS RESIDUES; CYTIDINE DEAMINASE; PROTEASOMAL DEGRADATION; SECONDARY STRUCTURES; SITE HETEROGENEITY; T CELLS; UBIQUITIN LIGASES; VIRION INFECTIVITY FACTORS; WILD TYPES; X-RAY ABSORPTION SPECTROSCOPY; ZINC BINDING;

ABSORPTION SPECTROSCOPY; AMINES; AMINO ACIDS; BINDING ENERGY; BIOMIMETICS; ENZYMES; LIGANDS; MACHINERY; ORGANIC ACIDS; PEPTIDES; PHOTODEGRADATION; X RAY SPECTROSCOPY;

ZINC;

CULLIN; CULLIN 5; CYSTEINE; HISTIDINE; UNCLASSIFIED DRUG; VIRION INFECTIVITY FACTOR; VIRUS PROTEIN; ZINC ION;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; WILD TYPE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; BIOMIMETICS; CARRIER PROTEINS; CONSERVED SEQUENCE; CULLIN PROTEINS; GENE PRODUCTS, VIF; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; ZINC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 69049101321     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi900677w     Document Type: Article

References (50)

1. Emerman, M., and Malim, M. H. (1998) HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280, 1880-1884.
2. Frankel, A. D., and Young, J. A. (1998) HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67, 1-25.
3. Strebel, K. (2003) Virus-host interactions: role of HIV proteins Vif, Tat, and Rev. AIDS 17 (Suppl. 4), S25-S34.
4. Strebel, K. (2007) HIV accessory genes Vif and Vpu. Adv. Pharmacol. 55, 199-232.
5. Schwartz, S., Felber, B. K., and Pavlakis, G. N. (1991) Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Revdependent and regulated by splicing. Virology 183, 677-686.
6. Garrett, E. D., Tiley, L. S., and Cullen, B. R. (1991) Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J. Virol. 65, 1653-1657.
7. Karczewski, M. K., and Strebel, K. (1996) Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J. Virol. 70, 494-507.
8. Camaur, D., and Trono, D. (1996) Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J. Virol. 70, 6106-6111.
9. Liu, H., Wu, X., Newman, M., Shaw, G. M., Hahn, B. H., and Kappes, J. C. (1995) The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J. Virol. 69, 7630-7638.
10. Borman, A. M., Quillent, C., Charneau, P., Dauguet, C., and Clavel, F. (1995) Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J. Virol. 69, 2058-2067.
11. Kishi, M., Nishino, Y., Sumiya, M., Ohki, K., Kimura, T., Goto, T., Nakai, M., Kakinuma, M., and Ikuta, K. (1992) Cells surviving infection by human immunodeficiency virus type 1: vif or vpu mutants produce non-infectious or markedly less cytopathic viruses. J. Gen. Virol. 73 (Part 1), 77-87.
12. Strebel, K., Daugherty, D., Clouse, K., Cohen, D., Folks, T., and Martin, M. A. (1987) The HIV "A" (sor) gene product is essential for virus infectivity. Nature 328, 728-730.
13. Fisher, A. G., Ensoli, B., Ivanoff, L., Chamberlain, M., Petteway, S., Ratner, L., Gallo, R. C., and Wong-Staal, F. (1987) The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237, 888-893.
14. von Schwedler, U., Song, J., Aiken, C., and Trono, D. (1993) Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67, 4945-4955.
15. Gabuzda, D. H., Lawrence, K., Langhoff, E., Terwilliger, E., Dorfman, T., Haseltine, W. A., and Sodroski, J. (1992) Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 66, 6489-6495.
16. Sakai, H., Shibata, R., Sakuragi, J., Sakuragi, S., Kawamura, M., and Adachi, A. (1993) Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J. Virol. 67, 1663-1666.
17. Fan, L., and Peden, K. (1992) Cell-free transmission of Vif mutants of HIV-1. Virology 190, 19-29.
18. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650.
19. Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., and Navaratnam, N. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296.
20. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S., and Malim, M. H. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809.
21. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103.
22. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., and Gao, L. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98.
23. Mehle, A.,Goncalves, J., Santa-Marta, M.,McPike, M., and Gabuzda, D. (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18, 2861-2866.
24. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X. F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060.
25. Yu, Y., Xiao, Z., Ehrlich, E. S., Yu, X., and Yu, X. F. (2004) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18, 2867-2872.
26. Conticello, S. G., Harris, R. S., and Neuberger, M. S. (2003) The Vif protein of HIV triggers degradation of the human antiretroviralDNA deaminase APOBEC3G. Curr. Biol. 13, 2009-2013.
27. Marin, M., Rose, K. M., Kozak, S. L., and Kabat, D. (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398-1403.
28. Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., and Gabuzda, D. (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279, 7792-7798.
29. Sheehy, A. M., Gaddis, N. C., and Malim, M. H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407.
30. Kile, B. T., Schulman, B. A., Alexander,W. S., Nicola, N. A., Martin, H. M., and Hilton, D. J. (2002) The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci. 27, 235-241.
31. Luo, K., Xiao, Z., Ehrlich, E., Yu, Y., Liu, B., Zheng, S., andYu, X. F. (2005) Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U.S.A. 102, 11444-11449
32. Mehle, A., Thomas, E. R., Rajendran, K. S., and Gabuzda, D. (2006) A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281, 17259-17265.
33. Paul, I., Cui, J., and Maynard, E. L. (2006) Zinc binding to theHCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 103, 18475-18480.
34. Giri,K., andMaynard,E.L. (2009) Conformational analysis of a peptide approximating the HCCH motif in HIV-1 Vif. Peptide Sci. (in press).
35. Xiao, Z., Ehrlich, E., Yu, Y., Luo, K., Wang, T., Tian, C., and Yu, X. F. (2006) Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349, 290-299.
36. Xiao, Z., Xiong, Y., Zhang, W., Tan, L., Ehrlich, E., Guo, D., and Yu, X. F. (2007) Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J. Mol. Biol. 373, 541-550.
37. Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4, 2411-2423.
38. Andrade, M. A., Chacon, P., Merelo, J. J., and Moran, F. (1993) Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng. 6, 383-390.
39. Lobley, A., Whitmore, L., and Wallace, B. A. (2002) DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra. Bioinformatics 18, 211-212.
40. Whitmore, L., and Wallace, B. A. (2004) DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 32, W668-W673.
41. Hunt, J. B., Neece, S. H., and Ginsburg, A. (1985) The use of 4-(2-pyridylazo)resorcinol in studies of zinc release from Escherichia coli aspartate transcarbamoylase. Anal. Biochem. 146, 150-157.
42. Gatto, G. J.Jr., Maynard, E. L., Guerrerio, A. L., Geisbrecht, B. V., Gould, S. J., and Berg, J. M. (2003) Correlating structure and affinity for PEX5:PTS1 complexes. Biochemistry 42, 1660-1666.
43. Ankudinov, A. L., Ravel, B., Rehr, J. J., and Conradson, S. D. (1998) Real-space multiple-scattering calculation and interpretation of xray-absorption near-edge structure. Phys. Rev. B 58, 7565-7576.
44. Wilson, C. L., Hubbard, S. J., and Doig, A. J. (2002) A critical assessment of the secondary structure alpha-helices and their termini in proteins. Protein Eng. 15, 545-554.
45. Jones, D. T. (1999) Protein secondary structure prediction based on position-specific scoring matrices. J. Mol. Biol. 292, 195-202.
46. Van Holde, K. E., Johnson, W. C., Jr., and Ho, P. S. (1998) Principles of Physical Biochemistry , Prentice-Hall, Upper Saddle River, NJ.
47. Harris, R. S. (2008) Enhancing immunity to HIV through APOBEC. Nat. Biotechnol. 26, 1089-1090.
48. Mehle, A., Wilson, H., Zhang, C., Brazier, A. J., McPike, M., Pery, E., and Gabuzda, D. (2007) Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81, 13235-13241.
49. Nathans, R., Cao, H., Sharova, N., Ali, A., Sharkey, M., Stranska, R., Stevenson, M., and Rana, T. M. (2008) Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26, 1187-1192.
50. Xiao, Z., Ehrlich, E., Luo, K., Xiong, Y., and Yu, X. F. (2007) Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21, 217-222.